Condition: Thyroid Associated Ophthalmopathies · Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
This description comes directly from the study's public registry record.
VP of R&D · 86 0571-86963293 · jwshi@minghuipharma.com
Always discuss trial participation with your own doctor first.
| Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06989918